BIOMED PHARMACOTHER 润色咨询

BIOMEDICINE & PHARMACOTHERAPY

出版年份:1982 年文章数:8228 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:10.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2024-04-10 ms7000000856963905 来自北京

    记录一下:
    2023年12月26号 投稿
    2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)
    2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)
    那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号
    2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收
    2024年4月4号 编辑决定accept
    2024年4月10号 online
    总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2024-04-06 14724b31m63暂无昵称 来自吉林省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:类风湿关节炎
    经验分享:11-17Submit New Manuscript
    12-7Submissions Sent Back to Author 要求更改WB原始数据格式
    12-13Submit New Manuscript
    1-11With editor
    1-14、1-16 1-17 1-29 Under review
    2-13 Required Reviews completed
    2-14Decision in progress
    2-17Revise
    3-7Revised Manuscript Submitted
    3-7Under Review
    3-15Revise
    3-28 Revision submitted to journal
    3-28Under Review
    4-1Required Reviews Completed
    4-4 Accepted

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2024-03-29 Zhou zhongsheng 来自吉林

    审稿速度:1.0
    偏重的研究方向:类风湿学研究;inflammation;免疫学研究
    经验分享:基础研究 今天接收了

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2024-01-31 ms8000001441772842 来自北京

    多久有人愿意审稿呀。

    5

    展开5条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2024-03-31 ms8000001441772842 来自北京

    有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2023-07-31 ms6000001702952186 来自湖南省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向:分子生物学;肿瘤;综述
    经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2023-09-04 ms5000000678442882 来自天津

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:综述
    经验分享:6.28 submit
    7.12 with editor
    7.14 under review
    8.7 revise
    8.21 revision submited to journal
    8.23 under review
    9.1 accept

    11

    展开11条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2022-04-18 奶油

    审稿速度:2.0
    经验分享:3.12 投稿
    3.15 with editor
    3.18 under review
    3.24 revise
    3.29 返稿
    4.7 revise
    4.13 返稿
    4.17 accept

    39

    展开39条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2197732, encodeId=af9a219e73285, content=记录一下:<br>2023年12月26号 投稿<br>2024年1月31号 under review(送了好几位审稿人,最后2位同意审稿)<br>2024年2月9号 1审意见返回,其中一位要求补实验,另一位回答疑问(要求2月29号前返修)<br>那段时间过年回家加上忙毕业论文,时间来不及,写信申请延长至3月31号<br>2024年3月31号 返修,其中一位审稿人疑似跑路,另一位审稿人建议接收<br>2024年4月4号 编辑决定accept<br>2024年4月10号 online<br>总之,期刊编辑还是很人性化,处理邮件也很及时,一审审稿人问题很有启发,补充实验后确实能提升文章水平,其中一位审稿人跑路也没重新送审(很多期刊遇到这种情况都是再次送审,就挺耽误时间)。<br><br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Wed Apr 10 13:17:44 CST 2024, time=2024-04-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197163, encodeId=f265219e16355, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:类风湿关节炎<br>经验分享:11-17Submit New Manuscript <br>12-7Submissions Sent Back to Author 要求更改WB原始数据格式<br>12-13Submit New Manuscript <br>1-11With editor <br>1-14、1-16 1-17 1-29 Under review <br>2-13 Required Reviews completed <br>2-14Decision in progress <br>2-17Revise <br>3-7Revised Manuscript Submitted <br>3-7Under Review<br>3-15Revise <br>3-28 Revision submitted to journal<br>3-28Under Review<br>4-1Required Reviews Completed<br>4-4 Accepted<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=573b5194794, createdName=14724b31m63暂无昵称, createdTime=Sat Apr 06 18:58:09 CST 2024, time=2024-04-06, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2195970, encodeId=73ac21959e084, content=审稿速度:1.0<br>偏重的研究方向:类风湿学研究;inflammation;免疫学研究<br>经验分享:基础研究 今天接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LGwYqgmFoyap9audhicmId1AYQCcnIVvAoAmdHmiajX9k5WVHDIlgiax3TlicR1HribCXAmfNV314FmY5NEboJFaMrg/132, createdBy=473a5250569, createdName=Zhou zhongsheng, createdTime=Fri Mar 29 02:34:14 CST 2024, time=2024-03-29, status=1, ipAttribution=吉林), GetPortalCommentsPageByObjectIdResponse(id=2185142, encodeId=63162185142c0, content=多久有人愿意审稿呀。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Wed Jan 31 23:23:06 CST 2024, time=2024-01-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2195921, encodeId=139a219592122, content=请问Rights & Access form sent to you for completion这个阶段不需要点击什么是嘛?是不是还没有到proof。 接收,proof,支付是三个邮件嘛?谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/0e14153e72354362b59e8a071c515255-bF5cocj4dNVm.png, type=image, width=781, height=315)], authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Thu Mar 28 19:40:17 CST 2024, time=2024-03-28, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2196372, encodeId=a13f21963e213, content=有所有作者签字**版权的环节嘛,为什么支付完钱,然后proof之外没有邮件提示所有作者签字**版权啦。谢谢!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22b46401167, createdName=ms8000001441772842, createdTime=Sun Mar 31 20:51:27 CST 2024, time=2024-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:分子生物学;肿瘤;综述<br>经验分享:接收了一篇综述,6.4投稿,7.12回来意见。7.28翻修,7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:综述<br>经验分享:6.28 submit<br>7.12 with editor<br>7.14 under review<br>8.7 revise<br>8.21 revision submited to journal<br>8.23 under review<br>9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1212093, encodeId=9bb612120939c, content=审稿速度:2.0<br>经验分享:3.12 投稿<br>3.15 with editor<br>3.18 under review<br>3.24 revise<br>3.29 返稿<br>4.7 revise<br>4.13 返稿<br>4.17 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c2a75489889, createdName=奶油, createdTime=Mon Apr 18 08:37:54 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172039, encodeId=78e921e2039b3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:基础article<br>经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:<br>8月底投稿<br>20天后with editor<br>2天后under review<br>10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。<br>天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审<br>11天后accept<br>注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a52b5395228, createdName=ms3000001076220736, createdTime=Thu Nov 30 10:30:33 CST 2023, time=2023-11-30, status=1, ipAttribution=湖北省)]
    2023-11-30 ms3000001076220736 来自湖北省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:基础article
    经验分享:经常刷论坛看看大家的新进展,总想着接收了来分享自己的流程,每天刷新系统,终于等来了accept,流程具体时间记不清楚了,大致回忆下:
    8月底投稿
    20天后with editor
    2天后under review
    10月初开始陆续回来外审意见,邀请了9个审稿人,3个审稿人接受审稿,审稿意见那是一个真刁钻,都是送命题,要求大修,感觉部分审稿人就存在偏见,没办法,谁让他们是审稿人呢,只能按要求办了。
    天天熬夜补实验,然后润色,1个多月后修回,编辑那里效率很高,当天就with editor,第二天再次送审
    11天后accept
    注:投稿的时候上传了所有原始数据,WB的图全是整膜,也上传了路线图,所以编辑那里过得快,没再补什么;感觉最近接收了好多综述,现在投稿的人太多了,14天很难处理得过来,后边的时间就会延长,送审了过后邮件会有链接追溯文章的状态,还可以用**订阅。接收后邮件里也有链接让确认,然后就是缴费,可以用支付宝、**直接支付,方便了很多,支付了再给Invoice

    11

    展开11条回复
共500条页码: 3/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分